Canada and other OECD20 countries launch a similar number of innovative medicines. However, our public plans reimburse 32 to 45 per cent less….
Our resource hub to discover reports, policy papers and other forms of informative content
Time to Listing: Canada’s public plans cover fewer new medicines and take longer than most OECD countries to approve them
Public plans in Canada cover fewer medicines than in other OECD20 countries and take longer to be approved. For rare-disease medicines, this gap is even larger….